Bolt Biotherapeutics, Inc. — Director's Dealing 2021

Feb 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Bolt Biotherapeutics, Inc. (BOLT)
CIK: 0001641281
Period of Report: 2021-02-04

Reporting Person: Novo Holdings A/S (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
COMMON STOCK	76903	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
SERIES A-1 PREFERRED STOCK	$		COMMON STOCK (1096323)		Direct
SERIES B PREFERRED STOCK	$		COMMON STOCK (2050758)		Direct
SERIES C-1 PREFERRED STOCK	$		COMMON STOCK (421670)		Direct
SERIES C-2 PREFERRED STOCK	$		COMMON STOCK (458337)		Direct

Footnotes

F1: Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the "Preferred Stock") will convert automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.